JP6574431B2 - Ｕｔｉ融合タンパク質 - Google Patents

Ｕｔｉ融合タンパク質 Download PDF

Info

Publication number
JP6574431B2
JP6574431B2 JP2016553562A JP2016553562A JP6574431B2 JP 6574431 B2 JP6574431 B2 JP 6574431B2 JP 2016553562 A JP2016553562 A JP 2016553562A JP 2016553562 A JP2016553562 A JP 2016553562A JP 6574431 B2 JP6574431 B2 JP 6574431B2
Authority
JP
Japan
Prior art keywords
uti
fusion protein
domain
seq
acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016553562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512058A (ja
JP2017512058A5 (enExample
Inventor
チェンバレン、アーロン
リウ、チャン
シュミット、マティアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Takeda GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda GmbH filed Critical Takeda GmbH
Publication of JP2017512058A publication Critical patent/JP2017512058A/ja
Publication of JP2017512058A5 publication Critical patent/JP2017512058A5/ja
Priority to JP2019109054A priority Critical patent/JP6938565B2/ja
Application granted granted Critical
Publication of JP6574431B2 publication Critical patent/JP6574431B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
JP2016553562A 2014-02-24 2015-02-23 Ｕｔｉ融合タンパク質 Active JP6574431B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019109054A JP6938565B2 (ja) 2014-02-24 2019-06-11 Ｕｔｉ融合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461943617P 2014-02-24 2014-02-24
US61/943,617 2014-02-24
PCT/US2015/017152 WO2015127391A1 (en) 2014-02-24 2015-02-23 Uti fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019109054A Division JP6938565B2 (ja) 2014-02-24 2019-06-11 Ｕｔｉ融合タンパク質

Publications (3)

Publication Number Publication Date
JP2017512058A JP2017512058A (ja) 2017-05-18
JP2017512058A5 JP2017512058A5 (enExample) 2018-04-05
JP6574431B2 true JP6574431B2 (ja) 2019-09-11

Family

ID=52629709

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016553562A Active JP6574431B2 (ja) 2014-02-24 2015-02-23 Ｕｔｉ融合タンパク質
JP2019109054A Active JP6938565B2 (ja) 2014-02-24 2019-06-11 Ｕｔｉ融合タンパク質
JP2021142544A Pending JP2022002513A (ja) 2014-02-24 2021-09-01 Ｕｔｉ融合タンパク質
JP2023108024A Pending JP2023123763A (ja) 2014-02-24 2023-06-30 Ｕｔｉ融合タンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019109054A Active JP6938565B2 (ja) 2014-02-24 2019-06-11 Ｕｔｉ融合タンパク質
JP2021142544A Pending JP2022002513A (ja) 2014-02-24 2021-09-01 Ｕｔｉ融合タンパク質
JP2023108024A Pending JP2023123763A (ja) 2014-02-24 2023-06-30 Ｕｔｉ融合タンパク質

Country Status (38)

Country Link
US (4) US9856310B2 (enExample)
EP (2) EP3110434B1 (enExample)
JP (4) JP6574431B2 (enExample)
KR (3) KR102722304B1 (enExample)
CN (2) CN106232135B (enExample)
AR (1) AR101597A1 (enExample)
AU (4) AU2015218704B2 (enExample)
BR (1) BR112016019390B1 (enExample)
CA (2) CA2939639C (enExample)
CL (1) CL2016002136A1 (enExample)
CR (1) CR20160444A (enExample)
CY (1) CY1120997T1 (enExample)
DK (1) DK3110434T3 (enExample)
DO (1) DOP2016000202A (enExample)
EA (2) EA037256B1 (enExample)
EC (1) ECSP16076535A (enExample)
ES (1) ES2700149T3 (enExample)
GE (2) GEP20196970B (enExample)
HR (1) HRP20182029T1 (enExample)
IL (1) IL247321B (enExample)
JO (1) JO3729B1 (enExample)
LT (1) LT3110434T (enExample)
MA (1) MA39347B2 (enExample)
MX (4) MX384070B (enExample)
MY (1) MY178774A (enExample)
NZ (3) NZ760008A (enExample)
PE (1) PE20170257A1 (enExample)
PH (1) PH12016501629B1 (enExample)
PL (1) PL3110434T3 (enExample)
PT (1) PT3110434T (enExample)
RS (1) RS58285B1 (enExample)
SG (2) SG10201708400QA (enExample)
SI (1) SI3110434T1 (enExample)
SM (1) SMT201800674T1 (enExample)
TW (1) TWI694084B (enExample)
UA (1) UA118866C2 (enExample)
WO (1) WO2015127391A1 (enExample)
ZA (1) ZA201606327B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939639C (en) * 2014-02-24 2023-01-24 Takeda Gmbh Uti fusion proteins
WO2018226887A1 (en) 2017-06-07 2018-12-13 Spark Therapeutics, Inc. ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION
WO2020106881A1 (en) * 2018-11-20 2020-05-28 Diamedica Inc. Modified ulinastatin polypeptides
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
JP7778077B2 (ja) * 2020-03-05 2025-12-01 ダイアメディカ ユーエスエー インコーポレイテッド ウリナスタチンポリペプチド
WO2022165031A1 (en) * 2021-01-29 2022-08-04 DiaMedica USA Inc. Ulinastatin polypeptides for treating diseases
CN116903721A (zh) * 2023-06-16 2023-10-20 成都佩德生物医药有限公司 多肽pdbpe-001、其药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
ATE114332T1 (de) 1989-05-13 1994-12-15 Bayer Ag Proteinaseninhibitoren, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel.
EP0486001A1 (en) 1990-11-13 1992-05-20 Mochida Pharmaceutical Co., Ltd. Recombinant urinary trypsin inhibitor fragments and drug composition
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
WO1997033996A2 (en) 1996-03-11 1997-09-18 Bayer Corporation Human bikunin
DE19725014A1 (de) 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
BRPI0509367A (pt) * 2004-03-30 2007-09-11 Glaxo Group Ltd anticorpo, fragmento de ligação de antìgeno, composição farmacêutica, métodos de tratar um paciente humano afligido com uma doença ou distúrbio, de triar um anticorpo, e de detectar hosm em uma amostra biológica, uso de um anticorpo terapêutico ou fragmento de ligação de antìgeno, medicamento, vetor, polunucleotìdeo, célula hospedeira recombinante estavelmente transformada ou transfectada, e, processo para a fabricação de um anticorpo terapêutico
KR20070041781A (ko) * 2004-08-11 2007-04-19 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인 융합 단백질
CN103665168A (zh) * 2005-06-03 2014-03-26 持田制药株式会社 抗cd14抗体融合蛋白质
EP1981519B1 (en) 2005-12-29 2017-12-27 Dyax Corp. Protease inhibition
US10407513B2 (en) * 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
CN102580085B (zh) * 2008-10-13 2013-09-18 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗脓毒症药物中的应用
AU2010246038A1 (en) * 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
EP3053932B1 (en) * 2010-02-19 2020-07-22 Xencor, Inc. Novel ctla4-ig immunoadhesins
CA2834626A1 (en) * 2011-04-29 2012-11-01 University Of Washington Therapeutic nuclease compositions and methods
US8619331B2 (en) 2011-07-19 2013-12-31 Xerox Corporation Simulated paper texture using clear toner and glossmark on texture-less stock
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
JP5855239B2 (ja) * 2012-04-23 2016-02-09 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
CN103044554B (zh) 2012-05-14 2014-08-27 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
CA2939639C (en) * 2014-02-24 2023-01-24 Takeda Gmbh Uti fusion proteins

Also Published As

Publication number Publication date
EA201691702A1 (ru) 2017-01-30
JP2019187427A (ja) 2019-10-31
AU2015218704A1 (en) 2016-09-22
AU2015218704B2 (en) 2019-05-02
RS58285B1 (sr) 2019-03-29
CN106232135A (zh) 2016-12-14
CN110092837B (zh) 2024-01-02
AU2019204448B2 (en) 2021-06-10
DOP2016000202A (es) 2016-12-15
PE20170257A1 (es) 2017-03-30
EP3110434B1 (en) 2018-09-19
CR20160444A (es) 2017-04-21
AU2021225156B2 (en) 2022-11-24
KR20160141718A (ko) 2016-12-09
DK3110434T3 (en) 2019-01-14
NZ760008A (en) 2023-03-31
JP2023123763A (ja) 2023-09-05
EA202091567A1 (ru) 2021-07-30
SMT201800674T1 (it) 2019-01-11
EP3110434A1 (en) 2017-01-04
US20220127334A1 (en) 2022-04-28
MX384070B (es) 2025-03-14
AU2023200875A1 (en) 2023-04-27
CY1120997T1 (el) 2019-12-11
ZA201606327B (en) 2019-01-30
AU2021225156A1 (en) 2021-09-30
MA39347B2 (fr) 2020-05-29
CN110092837A (zh) 2019-08-06
NZ724196A (en) 2022-01-28
JO3729B1 (ar) 2021-01-31
PH12016501629A1 (en) 2017-02-06
PL3110434T3 (pl) 2019-01-31
KR102722304B1 (ko) 2024-10-28
AU2019204448A1 (en) 2019-07-11
US10351618B2 (en) 2019-07-16
MX2024000004A (es) 2024-02-20
US20160362475A1 (en) 2016-12-15
PH12016501629B1 (en) 2023-10-20
MA39347A1 (fr) 2018-06-29
KR20240155987A (ko) 2024-10-29
JP6938565B2 (ja) 2021-09-22
GEP20196970B (en) 2019-04-25
CN106232135B (zh) 2019-12-10
NZ760789A (en) 2023-03-31
SG10201708400QA (en) 2017-11-29
CL2016002136A1 (es) 2017-08-11
US20180072795A1 (en) 2018-03-15
CA3178241A1 (en) 2015-08-27
JP2017512058A (ja) 2017-05-18
MY178774A (en) 2020-10-20
UA118866C2 (uk) 2019-03-25
BR112016019390B1 (pt) 2023-11-14
BR112016019390A2 (pt) 2017-10-24
PT3110434T (pt) 2018-12-19
ES2700149T3 (es) 2019-02-14
MX2016010950A (es) 2017-04-25
LT3110434T (lt) 2018-12-27
SG11201606691QA (en) 2016-09-29
US20200040062A1 (en) 2020-02-06
EA037256B1 (ru) 2021-02-26
TWI694084B (zh) 2020-05-21
TW201630931A (zh) 2016-09-01
KR20220151005A (ko) 2022-11-11
GEAP201814277A (en) 2018-12-25
MX2019013124A (es) 2020-08-31
AR101597A1 (es) 2016-12-28
KR102461210B1 (ko) 2022-10-31
JP2022002513A (ja) 2022-01-11
CA2939639A1 (en) 2015-08-27
EP3443978A1 (en) 2019-02-20
IL247321B (en) 2020-06-30
CA2939639C (en) 2023-01-24
SI3110434T1 (sl) 2019-02-28
WO2015127391A1 (en) 2015-08-27
US9856310B2 (en) 2018-01-02
IL247321A0 (en) 2016-09-29
ECSP16076535A (es) 2017-08-31
HRP20182029T1 (hr) 2019-02-08

Similar Documents

Publication Publication Date Title
AU2021225156B2 (en) UTI fusion proteins
JP6199033B2 (ja) 治療用ヌクレアーゼ組成物および方法
JP2022105200A (ja) ＡｐｏＡ－１融合ポリペプチドならびに関連する組成物および方法
JP2021506772A (ja) 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
JP2013253079A (ja) 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
HK40004244A (en) Uti fusion proteins
HK1232783B (en) Uti fusion proteins
HK1232783A1 (en) Uti fusion proteins
BR122023015739B1 (pt) Proteínas de fusão uti, seus usos, composição farmacêutica compreendendo a referida proteína e método de produção de uma proteína de fusão uti

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161110

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20161110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190816

R150 Certificate of patent or registration of utility model

Ref document number: 6574431

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250